Vor Biopharma (NYSE:VOR – Free Report) had its price objective trimmed by Stifel Nicolaus from $16.00 to $15.00 in a research report sent to investors on Friday, FlyOnTheWall reports. Other analysts have also issued research reports about the company. HC Wainwright reiterated a buy rating and set a $17.50 target price on shares of Vor […]